Hexarelin, Research Reference

Hexarelin (also known as Examorelin) is a synthetic hexapeptide consisting of six amino acids (His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2) and is regarded as the most potent growth hormone releasing peptide (GHRP) studied to date. It stimulates GH release via the ghrelin receptor (GHS-R1a) at potency exceeding GHRP-2, GHRP-6, and Ipamorelin at equivalent doses. In addition to GHS-R1a binding, Hexarelin binds CD36 (a scavenger receptor expressed in cardiac tissue) through a pathway independent of GH elevation, which has become a separate area of cardioprotection research.

Quick Reference

Overview

Hexarelin belongs to the GHRP class alongside GHRP-2, GHRP-6, and Ipamorelin. All members of this class share the ghrelin receptor (GHS-R1a) as their primary target but differ substantially in potency, selectivity, and off-target effects. Hexarelin occupies the high-potency end of the spectrum: it produces the largest GH pulses among the GHRPs but also produces the most pronounced cortisol and prolactin co-elevation.

Key pharmacological characteristics investigated in research include:

• Potency: Produces higher peak GH elevation than GHRP-2, GHRP-6, or Ipamorelin at equivalent doses; considered the strongest GHS-R1a agonist in the GHRP class
• Dual receptor binding: In addition to GHS-R1a, Hexarelin binds the CD36 scavenger receptor in cardiac tissue through a pathway that does not depend on GH elevation
• Desensitisation: GHS-R1a downregulation occurs faster with Hexarelin than with Ipamorelin or CJC-1295 due to higher receptor binding affinity and more complete receptor activation; cycling protocols are commonly reported to maintain response
• Off-target hormonal effects: Dose-dependent cortisol and prolactin elevation are consistently reported, making Hexarelin less selective than Ipamorelin

The original hexapeptide work was conducted by Bowers CY, who developed the GHRP series as part of broader investigations into growth hormone secretagogues. Hexarelin was used in human research trials as a diagnostic and investigational compound before the development of non-peptide GH secretagogues.

Hexarelin is not approved for human therapeutic use in any major jurisdiction and is classified as a research compound. It appears on the WADA Prohibited List.

Reported Protocols

The following information represents commonly reported research ranges drawn from anecdotal accounts and available research literature. These are not medical recommendations.

Subcutaneous Administration

Subcutaneous injection is the most commonly reported route in research accounts. Commonly reported doses range from 100 mcg to 200 mcg per injection, administered up to three times daily. Most anecdotal research protocols describe 100 mcg twice daily as the standard starting point.

• Dosing frequency: One to three injections per day are reported, typically timed before meals or before sleep to align with natural GH pulse windows
• Fasted state: Administration in a fasted state or at least 2 hours from a meal is commonly described. Elevated blood glucose and insulin are reported to blunt GH secretagogue response; fasted dosing is described as producing a more robust GH pulse
• Timing: Before-sleep injection is frequently described, as the largest natural GH pulse occurs during slow-wave sleep. Pre-workout timing is also reported in anecdotal accounts

Intramuscular Administration

Intramuscular injection is less commonly reported but is described in some research protocols. The pharmacokinetic difference between subcutaneous and intramuscular routes for Hexarelin has not been comprehensively studied in humans; the subcutaneous route is the more frequently documented approach.

Cycling to Address Desensitisation

Due to Hexarelin’s faster GHS-R1a desensitisation relative to other GHRPs, cycling is commonly described in research accounts. A frequently reported structure is 2 weeks on, followed by 2 weeks off, though 3-on/1-off and other patterns are also described. Some anecdotal researchers report rotating to Ipamorelin or CJC-1295 during the off-period to maintain GH axis stimulation while allowing GHS-R1a to resensitise.

Continuous daily administration over extended periods without cycling is associated in research accounts with a progressively attenuated GH response, making cycling the more commonly described approach for longer-duration protocols.

Combination With GHRH Analogues

Hexarelin, like other GHRPs, acts via the ghrelin receptor and can be combined with GHRH analogues (CJC-1295, Sermorelin) to produce synergistic GH release by targeting two independent receptor pathways simultaneously. Anecdotal research accounts describe this combination producing a larger GH pulse than either compound alone. Given Hexarelin’s greater off-target hormonal effects, some research accounts prefer combining a GHRH analogue with Ipamorelin rather than Hexarelin when cortisol and prolactin elevation are concerns.

Reported Effects

The following effects have been reported in preclinical research and anecdotal accounts. This list reflects the research landscape, not confirmed clinical outcomes.

Growth Hormone Release

Research has confirmed Hexarelin’s ability to stimulate potent pulsatile GH secretion from the anterior pituitary, with human studies demonstrating GH pulses exceeding those produced by GHRP-2, GHRP-6, and Ipamorelin at equivalent doses. The resulting elevation in circulating GH triggers hepatic IGF-1 production, which is proposed as the downstream mediator of anabolic and recovery effects.

Cardiac Protective Effects Via CD36

Research has investigated Hexarelin for its potential role in cardioprotection through the CD36 receptor pathway, independently of GH elevation. Muccioli et al. and Torsello et al. identified CD36 as a Hexarelin binding site in cardiac tissue, and animal model research has reported reduced myocardial ischaemia-reperfusion injury following Hexarelin administration. This cardiac research interest is considered a distinct property of Hexarelin not shared by other GHRPs that do not bind CD36.

Body Composition

Research has investigated Hexarelin for its potential role in body composition changes mediated downstream through GH and IGF-1, including lean mass accrual and fat mobilisation. Anecdotal accounts describe improvements in muscle fullness and gradual reductions in body fat over multi-week research periods, consistent with GH secretagogue effects described across the GHRP class.

IGF-1 Elevation

Downstream IGF-1 elevation is a commonly reported biomarker of Hexarelin’s biological activity over sustained protocols. IGF-1 mediates many of the anabolic effects attributed to GH elevation, including protein synthesis, nitrogen retention, and collagen production.

Anabolic and Recovery Effects

Anecdotal research accounts describe improved recovery from physical training and musculoskeletal stress. These reported effects are attributed in anecdotal accounts to the combined action of elevated GH and IGF-1 on protein synthesis and tissue repair processes.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following. This list does not constitute a comprehensive safety profile and should not be interpreted as predictive of individual outcomes.

Selectivity note: Unlike Ipamorelin, Hexarelin produces meaningful cortisol and prolactin elevation at research doses. The appetite stimulation is also more pronounced than with Ipamorelin and is more comparable to that reported with GHRP-6. Researchers for whom cortisol elevation or appetite stimulation are concerns frequently describe preferring Ipamorelin or GHRP-2.

Desensitisation note: Hexarelin’s faster GHS-R1a downregulation compared with other GHRPs means that the GH response may attenuate more rapidly during continuous daily use. This is commonly managed through cycling protocols as described above.

The compound has not undergone comprehensive long-term human safety trials.

Storage & Handling

Lyophilized Powder (Unreconstituted)

• Refrigerator (2–8°C): Preferred for extended storage; commonly reported stable for 12 months or more
• Room temperature: Short-term stability acceptable when kept away from light and moisture; refrigerator storage preferred
• Freezer: Acceptable for long-term storage; avoid repeated freeze-thaw cycles
• Light sensitivity: Store in an opaque or amber vial; protect from direct light exposure

Reconstituted Solution

• Refrigerator (2–8°C): Use within 4–6 weeks of reconstitution
• Do not freeze a reconstituted solution
• Bacteriostatic water (BAC water) is the standard diluent for multi-dose vials; the benzyl alcohol preservative extends refrigerated shelf life
• Discard if the solution becomes cloudy, discoloured, or shows particulate matter

Reconstitution

Add bacteriostatic water slowly to the lyophilized vial along the inside wall. Swirl gently, do not shake. See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

How does Hexarelin compare to Ipamorelin? Hexarelin produces a higher peak GH pulse than Ipamorelin at equivalent doses and is considered the most potent GHRP studied. However, Ipamorelin is selective for GH and produces minimal cortisol, prolactin, or appetite effects. Hexarelin produces dose-dependent cortisol and prolactin elevation alongside its GH release, and causes more pronounced hunger stimulation. Researchers prioritising maximal GH amplitude may select Hexarelin; those prioritising a clean side effect profile typically select Ipamorelin.

Why does desensitization occur faster with Hexarelin than with other GHRPs? Hexarelin’s high binding affinity for GHS-R1a and its more complete receptor activation lead to faster GHS-R1a downregulation compared with Ipamorelin or CJC-1295. Continuous daily use over several weeks is associated with an attenuated GH response in research accounts. Cycling protocols, commonly reported as 2 weeks on and 2 weeks off or similar structures, are described as a means of maintaining GH pulse response over longer research periods.

What is the cardiac research angle for Hexarelin? Hexarelin binds not only GHS-R1a but also CD36, a scavenger receptor expressed in cardiac tissue. This CD36 binding pathway is independent of GH elevation and has been associated with cardioprotective effects in animal models, including reduced myocardial ischaemia-reperfusion injury. Research by Muccioli, Torsello, and others has investigated this pathway. The cardiac effects are considered a distinct research interest from Hexarelin’s GH-stimulating properties.

Should Hexarelin be cycled? Cycling is commonly reported in anecdotal research accounts due to Hexarelin’s faster GHS-R1a desensitisation relative to other GHRPs. A commonly described structure is 2 weeks on followed by 2 weeks off, though other cycle lengths are reported. Continuous daily administration over extended periods is associated in research accounts with progressively blunted GH responses. Rotating to a different secretagogue during the off period is also described in some protocols.

Related Pages

Goals: Muscle Growth & Body Composition · Athletic Performance & Endurance

Class: GHRPs, Growth Hormone Releasing Peptides

Also see: Ipamorelin · GHRP-2 · GHRP-6

Comparisons: Ipamorelin vs Hexarelin

Mechanisms: Growth Hormone Secretion · Ghrelin Receptor

References & Further Reading

• Bowers CY. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12), 1316–1329. PubMed →
• Muccioli G, et al. (2004). Hexarelin and synthetic GHS interact with a novel receptor distinct from GHS-R1a in the cardiovascular system. Journal of Endocrinology, 181(1), 45–54. PubMed →
• Torsello A, et al. (2003). Hexarelin protects against doxorubicin-induced cardiomyopathy in the rat. Endocrinology, 144(11), 4780–4788. PubMed →
• Ghigo E, et al. (1994). Hexarelin, a new synthetic hexapeptide, stimulates the release of growth hormone, cortisol, ACTH and PRL in man. Journal of Endocrinological Investigation, 17(9), 717–723. PubMed →
• Loche S, et al. (1995). Effects of hexarelin (growth hormone releasing hexapeptide) in children with short stature. Journal of Endocrinological Investigation, 18(9), 722–726. PubMed →